- Home
- SLI vs ZVRA Comparison
SLI vs ZVRA Comparison
Compare SLI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLI
- ZVRA
- Stock Information
- Founded
- SLI 1998
- ZVRA 2006
- Country
- SLI Canada
- ZVRA United States
- Employees
- SLI N/A
- ZVRA N/A
- Industry
- SLI Major Chemicals
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- SLI Industrials
- ZVRA Health Care
- Exchange
- SLI Nasdaq
- ZVRA Nasdaq
- Market Cap
- SLI 406.1M
- ZVRA 473.6M
- IPO Year
- SLI N/A
- ZVRA 2015
- Fundamental
- Price
- SLI $1.72
- ZVRA $9.59
- Analyst Decision
- SLI Strong Buy
- ZVRA Strong Buy
- Analyst Count
- SLI 1
- ZVRA 7
- Target Price
- SLI $3.50
- ZVRA $21.20
- AVG Volume (30 Days)
- SLI 2.2M
- ZVRA 709.1K
- Earning Date
- SLI 11-12-2024
- ZVRA 11-12-2024
- Dividend Yield
- SLI N/A
- ZVRA N/A
- EPS Growth
- SLI N/A
- ZVRA N/A
- EPS
- SLI 0.61
- ZVRA N/A
- Revenue
- SLI N/A
- ZVRA $24,489,000.00
- Revenue This Year
- SLI N/A
- ZVRA N/A
- Revenue Next Year
- SLI N/A
- ZVRA $318.48
- P/E Ratio
- SLI $2.92
- ZVRA N/A
- Revenue Growth
- SLI N/A
- ZVRA 47.85
- 52 Week Low
- SLI $1.05
- ZVRA $4.20
- 52 Week High
- SLI $2.64
- ZVRA $9.64
- Technical
- Relative Strength Index (RSI)
- SLI 41.54
- ZVRA 67.47
- Support Level
- SLI $1.60
- ZVRA $8.32
- Resistance Level
- SLI $1.82
- ZVRA $9.21
- Average True Range (ATR)
- SLI 0.16
- ZVRA 0.54
- MACD
- SLI -0.07
- ZVRA 0.04
- Stochastic Oscillator
- SLI 18.59
- ZVRA 96.94
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, Tetra Project, and Bristol Dry Lake Project.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.